Health1 min read

STAT+: After death in gene therapy trial for a brain disease, progress is reported

By · Via STAT Health · Published by Everything Blog

In short

Scientists investigating a fatal complication in a neurological clinical trial have presented detailed findings to help restore confidence across the sector. Although the exact trigger for the fatality remains undetermined, teams are actively designing new experimental protocols to safely advance future candidates. Industry leaders believe this emerging evaluation framework will allow developers to test, predict, and counter the novel safety risk in subsequent studies. The patient fatality occurred last year, initially generating widespread fear among researchers pursuing neurological treatments.

Key points

  • An investigation into the clinical trial fatality failed to identify the exact cause of t…: An investigation into the clinical trial fatality failed to identify the exact cause of the patient's death.
  • Researchers have proposed new experimental designs to properly evaluate prospective neuro…: Researchers have proposed new experimental designs to properly evaluate prospective neurological therapies moving forward.
  • Experts believe the novel safety risk uncovered in the study can be predicted and mitigat…: Experts believe the novel safety risk uncovered in the study can be predicted and mitigated in upcoming trials.

Sources checked by our analysis pipeline: 1

Researchers on Friday presented detailed investigations into a gene therapy death that sparked fear and uncertainty last year among scientists who felt they had been approaching powerful treatments for a long list of brain diseases.

The researchers did not conclude precisely what led to the patient’s death but proposed experiments to screen future therapies.

“What I want everyone to take home is: I think we’re starting to build a framework for testing this,” said Nicholas Flytzanis, chief research and innovation officer at Capsida Biotherapeutics. “I think it can be tested, and I think this specific novel risk is one that we can try to mitigate and predict in the future.”

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Health